Natto

Natto delivers nattokinase (a 28 kDa fibrinolytic protease), menaquinone-7 (MK-7/vitamin K₂), γ-polyglutamic acid, and a metabolome of 569 unique compounds generated through Bacillus subtilis fermentation, collectively modulating coagulation, bone metabolism, and antioxidant defense pathways. A meta-analysis of clinical studies demonstrated that habitual natto intake elevates serum MK-7 levels (effect size d = 2.10, 95% CI [1.55, 2.66]) and produces a modestly significant increase in bone mineral density (d = 0.65, 95% CI [0.09, 1.21]).

Origin & History

Natto is a traditional Japanese fermented food produced from cooked soybeans (Glycine max) inoculated with Bacillus subtilis var. natto, a bacterium native to rice straw historically used to wrap the fermenting beans. Originating in the Kanto region of Japan over a millennium ago, natto production spread throughout Japan as a dietary staple prized for its shelf stability and dense nutritional profile. Today, natto is commercially produced under controlled fermentation conditions at approximately 40°C for 16–24 hours, with soybean variety, bacterial strain, and processing parameters critically influencing the final bioactive composition.

Historical & Cultural Context

Natto's origins in Japan are traditionally traced to the early Heian period (approximately 10th–11th century CE), with one popular legend attributing its discovery to Yoshiie Minamoto, whose troops accidentally fermented soybeans wrapped in straw during a military campaign. For centuries, natto was prepared by wrapping steamed soybeans in rice straw naturally colonized by Bacillus subtilis, allowing spontaneous fermentation at ambient temperature; industrial production replaced straw with controlled B. subtilis starter cultures in the 20th century. In Japanese folk medicine, natto has long been credited with promoting longevity, circulatory health, and digestive robustness, overlapping with the modern scientific discovery of nattokinase by Dr. Hiroyuki Sumi at Chicago University in 1980. Regional preferences within Japan vary significantly—Kanto consumers favor the softer Okame-style natto, while Kansai populations have historically shown lower consumption rates—creating natural epidemiological gradients that have informed epidemiological research on natto's health effects.

Health Benefits

- **Cardiovascular and Thrombotic Risk Reduction**: Nattokinase directly hydrolyzes fibrin clots and activates endogenous plasminogen, reducing thrombus burden; habitual consumption is associated with lower markers of hypercoagulability in observational data from Japanese cohorts.
- **Bone Mineral Density Support**: MK-7 at approximately 380 μg per 50-g serving carboxylates osteocalcin, directing calcium into bone matrix; meta-analysis confirms natto intake modestly increases BMD (d = 0.65) and reduces undercarboxylated osteocalcin (d = −0.50).
- **Isoflavone-Mediated Antioxidant and Estrogenic Activity**: Fermentation amplifies genistein content to 16.4 times that of raw soybeans and glycine glycosides to 11.4 times, enabling enhanced estrogen receptor beta binding and free-radical scavenging relevant to post-menopausal bone and cardiovascular health.
- **Antimicrobial and Anticancer Potential**: Natto polypeptides exhibit antibacterial effects in culture, while natto freeze-drying extract (NFDE) and natto water extract (NWE) induce autophagy at low concentrations (<3 μg/mL) and shift to apoptosis at higher concentrations (5 μg/mL), suggesting concentration-dependent anticancer mechanisms.
- **Antiviral Defense**: Deoxyelephantopin, present at 105 times the concentration found in raw soybeans, demonstrates free-radical scavenging and direct antiviral activity against influenza A and herpes simplex virus in preclinical models.
- **Gut Microbiome Modulation**: Viable Bacillus subtilis spores in natto function as spore-forming probiotics that transiently colonize the gastrointestinal tract, modulating luminal pH and competitive exclusion of pathogens, with γ-polyglutamic acid acting as a prebiotic substrate.
- **Vitamin B12 Supplementation (Vegan Contexts)**: Natto is one of the few plant-derived foods containing biologically active cobalamin (vitamin B12) produced de novo by B. subtilis, offering a dietary source for populations avoiding animal products, though B12 content is variable and strain-dependent.

How It Works

Nattokinase exerts fibrinolytic activity by directly cleaving fibrin at specific peptide bonds and by activating tissue plasminogen activator (tPA) and urokinase, effectively dissolving established thrombi; it is heat-stable up to 60°C and functional across a wide pH range (6–12), suggesting partial enzymatic survival through the upper gastrointestinal tract. Menaquinone-7 (MK-7) functions as an essential cofactor for γ-glutamyl carboxylase, the enzyme responsible for carboxylating vitamin K-dependent proteins including osteocalcin (bone), matrix Gla protein (vascular calcification prevention), and coagulation factors II, VII, IX, and X. Genistein and other amplified isoflavones bind estrogen receptor beta with moderate affinity, modulating gene expression involved in osteoblast differentiation, lipid metabolism, and inflammatory cytokine production, while also inhibiting tyrosine kinase activity relevant to cell proliferation pathways. Deoxyelephantopin and the broader pool of 45 phenolic compounds and 70 flavonoids identified by metabolomic analysis collectively neutralize reactive oxygen species through electron donation and metal chelation, protecting cellular membranes and DNA from oxidative damage.

Scientific Research

The strongest and most quantified clinical evidence for natto centers on its MK-7 content and bone health outcomes: a published meta-analysis of multiple controlled studies found that habitual natto intake significantly elevated serum MK-7 (d = 2.10), increased carboxylated osteocalcin (d = 0.26), decreased undercarboxylated osteocalcin (d = −0.50), and produced modest but statistically significant gains in bone mineral density (d = 0.65), establishing moderate-to-strong evidence in this domain. Nattokinase has been evaluated in small human trials and in vitro fibrinolytic assays demonstrating enzymatic clot dissolution activity, but large-scale randomized controlled trials with clinical cardiovascular endpoints remain limited, placing cardiovascular evidence at a preliminary-to-moderate tier. Metabolomic studies have comprehensively catalogued 569 bioactive metabolites in natto—including 70 flavonoids, 60 amino acids, 76 alkaloids, 45 phenolics, and 27 nucleotides—providing a rigorous biochemical foundation, but most antimicrobial, antiviral, and anticancer findings rely on in vitro cell culture models without human translation data. The vitamin B12 content of natto has been confirmed analytically, but clinical trials specifically quantifying its efficacy as a B12 source in deficient populations are sparse, requiring cautious interpretation.

Clinical Summary

The most robust clinical dataset for natto comes from meta-analytic aggregation of studies examining MK-7-mediated bone outcomes, demonstrating a large effect on serum MK-7 elevation (d = 2.10, 95% CI [1.55, 2.66]), a small-to-moderate reduction in undercarboxylated osteocalcin (d = −0.50, 95% CI [−0.74, −0.26]), and a modest increase in bone mineral density (d = 0.65, 95% CI [0.09, 1.21]), with confidence intervals excluding zero across all primary endpoints. Nattokinase cardiovascular trials have demonstrated ex vivo and plasma fibrinolytic activity improvements, but these studies are generally small, lack standardized NK dosing across products, and have not yet reported hard cardiovascular event data in phase III trials. Anticancer investigations using NFDE and NWE represent early-phase cell line research showing concentration-dependent autophagy-to-apoptosis transitions, which are mechanistically intriguing but not yet supported by human trial data. Overall clinical confidence is highest for vitamin K₂/bone endpoints, moderate for nattokinase fibrinolytic biomarkers, and preliminary for antiviral, antimicrobial, and oncological applications.

Nutritional Profile

Per 100 g of natto: approximately 18 g protein, 11 g fat (predominantly polyunsaturated), 12 g carbohydrate, and 5 g dietary fiber, with a caloric density of approximately 212 kcal. Micronutrient highlights include vitamin K₂ (MK-7) at approximately 760 μg/100 g—the highest known dietary concentration globally—along with meaningful amounts of iron (~3.6 mg), manganese (~1.5 mg), copper, magnesium (~115 mg), and phosphorus (~190 mg). The fermentation process substantially elevates bioavailability of isoflavones (genistein 16.4-fold vs. raw soybeans), generates de novo vitamin B12, and converts bound phytate-complexed minerals into more absorbable free ionic forms. The amino acid profile per 100 g includes glutamate (3.4 g), leucine (1.6 g), and proline (1.5 g), along with 14 total quantified amino acids; γ-polyglutamic acid (γ-PGA) is a unique fermentation-derived polymer contributing to the characteristic viscous texture and potentially enhancing mineral absorption in the gut.

Preparation & Dosage

- **Traditional Whole Food (Japan)**: Standard serving is 40–100 g of fermented soybeans per day, providing approximately 304–760 μg MK-7 and meaningful nattokinase activity; consumed typically at breakfast over rice.
- **Nattokinase Capsules/Tablets**: Standardized to fibrinolytic units (FU); commonly marketed at 1,000–4,000 FU per capsule (equivalent to approximately 100–400 mg nattokinase extract); clinical protocols have used 2,000 FU twice daily, best taken on an empty stomach to maximize gastric survival.
- **MK-7 Isolated Supplements (Natto-Derived)**: Purified MK-7 at 90–360 μg/day mirrors the dose found in standard natto servings; 180–360 μg/day used in bone health trials; take with a fat-containing meal for optimal absorption as MK-7 is fat-soluble.
- **Natto Freeze-Dried Extract (NFDE) / Powder**: Used in research formulations; concentrates nattokinase, isoflavones, and γ-PGA; no universally standardized commercial dose established.
- **Probiotic/Spore Supplement (B. subtilis natto)**: Available as spore preparations at 1–10 billion CFU per serving; distinct from nattokinase supplements and intended for gut modulation rather than fibrinolytic effects.
- **Timing Note**: Nattokinase supplements are generally recommended away from anticoagulant medication administration windows and should be discontinued at least one week before elective surgery due to fibrinolytic activity.

Synergy & Pairings

Natto's MK-7 works synergistically with vitamin D3, which upregulates osteocalcin gene transcription and increases the substrate available for K₂-dependent carboxylation, making a combined MK-7 (180–360 μg) plus D3 (1,000–2,000 IU) stack a well-supported strategy for bone mineral density optimization supported by multiple intervention studies. Nattokinase fibrinolytic activity may complement omega-3 fatty acids (EPA/DHA), which reduce platelet aggregation and inflammatory thrombus formation through COX and lipoxygenase pathway modulation, providing complementary antithrombotic mechanisms at the enzymatic and lipid mediator levels respectively; however, this combination amplifies bleeding risk and requires clinical caution. Natto's prebiotic γ-PGA component may enhance the efficacy of co-administered probiotic formulations by providing a fermentable substrate that sustains probiotic colony viability in the colon, making natto a logical whole-food adjunct to multi-strain probiotic protocols.

Safety & Interactions

Natto and nattokinase supplements are generally well tolerated at typical dietary serving sizes, with the primary safety concern being enhanced anticoagulant and antiplatelet activity; concurrent use with warfarin (Coumadin) creates a dual interaction—nattokinase amplifies fibrinolysis while the high MK-7 content (a vitamin K₂ source) can competitively antagonize warfarin's vitamin K epoxide reductase inhibition, making INR unpredictable and potentially dangerous. Individuals receiving anticoagulants (warfarin, rivaroxaban, apixaban, dabigatran), antiplatelet agents (aspirin, clopidogrel), or thrombolytic therapies should avoid therapeutic nattokinase supplementation except under direct medical supervision with coagulation monitoring. Soy allergy represents an absolute contraindication; individuals with thyroid dysfunction should be aware that soy isoflavones at high intake levels may modestly inhibit thyroid peroxidase, and timing of natto consumption relative to thyroid hormone medication should be spaced by at least four hours. Pregnancy and lactation safety data for supplemental-dose nattokinase or concentrated MK-7 extracts are insufficient to establish safety beyond normal dietary natto intake; pregnant individuals on vitamin K-restricted protocols (rare) should consult their obstetrician before regular natto consumption.